The aim of the first trials will be to show that these vaccine candidates are safe and can reduce the burden of infectious mono nucleosis. This illness causes symptoms including extreme fatigue and fever, and affects 30 to 50 % of people who contract e b v for the first time as teen ages or young adults. On average it takes around ten years for a vaccine to run the clinical trial gauntlet. After approval, observational data would take many more years to accumulate.

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode